Education
About Us
Working with TipRanks
Follow Us
Neurocrine (NBIX)
NASDAQ:NBIX
Earnings Data
Report Date
Aug 05, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.98Last Year’s EPS
0.63Same Quarter Last Year
Strong Buy
Based on 22 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 05, 2025
|% Change Since: 9.50%
|Next Earnings Date:Aug 05, 2025
Earnings Call Sentiment|Positive
The earnings call reflected strong performance in new patient starts for INGREZZA and a successful launch of CRENESSITY, highlighting significant achievements in R&D and financial strength. However, challenges in reauthorization and the impact of the Inflation Reduction Act were noted, affecting reimbursement dynamics and sales. Despite these challenges, the company remains well-positioned for future growth.Company Guidance
During the Q1 2025 earnings call, Neurocrine Biosciences provided guidance on several key metrics and forward-looking statements. The company reaffirmed its 2025 sales guidance for INGREZZA, projecting a range of $2.5 billion to $2.6 billion, despite a challenging first quarter affected by one less order week, patient reauthorization processes, and gross-to-net dynamics. The quarter saw record new patient starts for INGREZZA and a promising early adoption of CRENESSITY, which achieved $15 million in net revenue from 413 enrollment forms with 70% of dispenses receiving reimbursement. Neurocrine also reported a strong financial foundation with approximately $1.8 billion in cash, enabling continued investment in their robust clinical pipeline. On the R&D front, the company highlighted the progression of osavampator and NBI-'568 into Phase 3 registrational studies, as well as plans to expand their muscarinic portfolio into new Phase 2 studies later this year. The call also noted the strategic transition in leadership, with Dr. Sanjay Keswani set to join as the new Chief Medical Officer.Record New Patient Starts for INGREZZA
The first quarter reflected strong execution across both brands with record new patient starts for INGREZZA.
Successful Launch of CRENESSITY
Neurocrine reported encouraging early adoption of CRENESSITY, achieving net revenue of $15 million in its first full quarter of launch.
Advancement in R&D Portfolio
Progression of osavampator and NBI-'568 into Phase 3 registrational studies, with further expansion of the muscarinic portfolio into new Phase 2 studies later this year.
Financial Strength and Flexibility
Retained a strong balance sheet with approximately $1.8 billion in cash to support commercial and clinical development strategies for continued growth.
Increase in Formulary Coverage
Expanded formulary coverage in Medicare Part D, significantly increasing patient access and providing a foundation to expand the customer base.
NBIX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
NBIX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 05, 2025 | $109.75 | $118.92 | +8.36% |
Feb 06, 2025 | $150.51 | $122.62 | -18.53% |
Oct 30, 2024 | $116.19 | $124.33 | +7.01% |
Aug 01, 2024 | $141.57 | $153.15 | +8.18% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Neurocrine (NBIX) report earnings?
Neurocrine (NBIX) is schdueled to report earning on Aug 05, 2025, TBA Not Confirmed.
What is Neurocrine (NBIX) earnings time?
Neurocrine (NBIX) earnings time is at Aug 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NBIX EPS forecast?
NBIX EPS forecast for the fiscal quarter 2025 (Q2) is 0.98.